Qiagen downgraded to Equal Weight from Overweight at Barclays

Barclays downgraded Qiagen (QGEN) to Equal Weight from Overweight with a price target of $44, down from $58. The firm now sees the company’s takeout potential as less likely. Qiagen has high U.S. academic and government exposure, which creates added risk into the Q1 report, the analyst tells investors in a research note. In addition, Roche is potentially entering the latent tuberculosis and syndromic testing markets, the analyst tells investors in a research note.